Wedbush Maintains Outperform on Palantir, $230 Price Target

1 min read Reproduced verbatim
Rating
Outperform
Unchanged
Target
$230
Unchanged
Upside
+48%
PLTR at $155 today
Wedbush and Palantir logos

What the analyst said

Wedbush analyst Dan Ives reiterated an Outperform rating and $230.00 price target on Palantir (NASDAQ: PLTR).

“The company beat the Street across all FY2Q26 metrics while raising its FY26 guidance across the board (yet again) including commentary around FY27 US commercial growth as the company continues to capitalize on elevated demand for its AI capabilities while focused on driving leverage into its business to drive further profitable growth.

FY26 revenue is expected to be in the range of $7.650 billion to $7.662 billion (prior guidance of $7.182 billion to $7.198 billion) vs. the Street’s $7.240 billion with US commercial expected to grow 120% y/y (prior guidance of at least 115% y/y) as AIP continues to capture greater spending across new and existing enterprises.

We note that Karp stated that he expects PLTR to grow revenue in US Commercial 100% y/y in FY27 pointing to the long-term opportunity the company is seeing with commercial customers lining up at PLTR’s door to tap into the most advanced AI products on the market.

FY26 adj. operating income is now expected to be in the range of $4.440 billion to $4.452 billion (prior guidance of $4.126 billion to $4.142 billion) while FY26 FCF is expected to be in the range of $4.200 billion to $4.400 billion (prior guidance of $3.925 billion to $4.125 billion) as PLTR continues to put up strong revenue metrics while maintaining a lower employee headcount.

Palantir remains one of our top tech names to own in 2026 and this quarter represents yet another validation moment for PLTR by continuously generating unprecedented traction for across the federal and commercial landscapes.”

Disclaimer
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.

This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.

Where the price stands

PLTR trades at $155. The 18 analysts who set a target in the last 3 months range from $130 to $273, with a median of $250. This $230 target is 8% below the median.

Since the note PLTR has moved +6% (from $146). 12-month window: day 184 of 365, closes on May 5, 2027.

Track record

This callOpen: PLTR has not reached $230 yet. This 12-month target is scored on May 5, 2027.

Firm track recordWedbush: 65% of its 23 targets at least a year old were reached within 12 months (#20 of 26 firms); on Palantir, 5 of 6. Accuracy ranking →

Earnings reactionOne of 10 notes after Palantir’s May 4 results: 1 raised · 1 cut · 5 kept. See every call →

Wedbush on Palantir

Wedbush price targets on Palantir

8 calls from May 6, 2025 to June 24, 2026. The target went from $140 to $230 (+64%). The rating stayed Buy.

Wedbush targetPLTR share price
  1. June 24, 2026Kept the $230 targetBuy$230
  2. June 5, 2026Kept the $230 targetBuy$230
  3. May 5, 2026 This noteKept the $230 targetBuy$230
  4. February 3, 2026Kept the $230 targetBuy$230
  5. November 3, 2025Target raised from $200 (+15%)Buy$230
  6. August 5, 2025Target raised from $160 (+25%)Buy$200
  7. July 10, 2025Target raised from $140 (+14%)Buy$160
  8. May 6, 2025Earliest call shownBuy$140
Share
Share on
Price Target is an archive of Wall Street analyst research, published for informational purposes only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell any security. Analyst ratings and price targets are the opinions of the issuing firms, not of Price Target. Always do your own research or consult a licensed financial adviser.